KR900701288A - 고혈압의 치료 - Google Patents
고혈압의 치료Info
- Publication number
- KR900701288A KR900701288A KR1019900701332A KR900701332A KR900701288A KR 900701288 A KR900701288 A KR 900701288A KR 1019900701332 A KR1019900701332 A KR 1019900701332A KR 900701332 A KR900701332 A KR 900701332A KR 900701288 A KR900701288 A KR 900701288A
- Authority
- KR
- South Korea
- Prior art keywords
- potassium
- hypertension
- salt
- human body
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Display Devices Of Pinball Game Machines (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본태성 고혈압을 갖는 두명의 남자 환자에게, 각각 15일동안 4회 경구투여로 200mmo1e/70kg 체중/일의 중탄산 칼륨을 투여한 곁과를 나타낸 그래프.
제2도는 5명의 정압성 남성에게 8일동안 1일에 70kg 체중당 약 100mmo1es의 중탄산 칼륨을 투여한 결과를 나타낸 제1도와 유사한 그래프.
제3도는 6명의 폐경후 정압성 여성에 대해 시간에 대한 평균 수축기와 이완기 MAP값에 대한 각각의 그래프로 제1도 및 제2도와 유사한 또 다른 그래프.
Claims (20)
- 약리적으로 허용 가능한 비-할로겐 음이온의 칼륨염을 포함하는 조성물의 치료량을 투여함으로 이루어지는, 인체내 고혈압증 치료방법
- 제1항에 있어서, 고혈압 환자 또는 고혈압을 일으키기 쉬운 정압성 환자를 상기 칼륨염을 사용하여 치료함으로 이루어지는, 인체내 고혈압증 치료방법.
- 제1항에 있어서, 상기 칼륨염은 중탄산 칼륨, 인산칼륨, 글루콘산 칼륨및 시트르산 칼륨으로 이루어진 그룹에서 선택됨을 특징으로 하는 방법.
- 제3항에 있어서, 상기 염이 중탄산 칼륨임을 특징으로 하는 방법.
- 제3항에 있어서, 칼륨염이 식이 보충물로 투여됨을 특징으로 하는 방법
- 중탄산 칼륨을 포함하는 조성물의 치료적 유효량을 투여함으로 이루어지는 인체내 고혈압증 치료방법.
- 제6항에 있어서, 고혈압 환자 또는 고혈압을 일으키기 쉬운 정압성 환자를 상기 중탄산 칼륨 조성물을 사용하여 치료함으로 이루어지는 인체내 고혈압중 치료방법.
- 제6항에 있어서, 중탄산 칼륨을 경구적으로 투여함을 특징으로 하는 방법.
- 제8항에 있어서, 중탄산 칼륨이 식이 보충물로 투여됨을 특징으로 하는 방법.
- 제6항에 있어서, 중탄산 칼륨이 약 50-200mmo1es/77kg 체중/24시간의 양으로 투여됨을 특징으로 하는 방법.
- 제6항에 있어서, 조성물은 제약적으로 허용 가능한 담체를 포함함을 특징으로 하는 방법.
- 중탄산 칼륨 및 인산 칼륨으로 이루어진 그룹에서 선택된 비-할로겐화 칼륨염을 환자의 동맥 혈압을 저하시키기에 충분한 앙으로, 상기 환자에게 투여함으로 이루어지는, 고헐압을 일으키기 쉬운 정압성 환자내 고혈압증의 발생을 방지하는 방법.
- 인체의 혈압을 측정하며 제1값을 얻고, 비-할로겐화 칼륨염을 상기 인체에 투여하며, 혈압을 측정하여 제2값을 얻은 후, 제1값과 제2값을 비교하고, 그로부터 상기 인체를 진단함으로 이루어지는 비-할로겐화 칼륨염으로 치료 가능한 고혈압증을 앓고 있는 환자 또는 고혈압에 걸리기 쉬운 인체를 진단하는 방법.
- 제13항에 있어서, 비-할로겐화 칼륨염을 비-할로겐화 치료법 또는 예방법에 감응하는 인체내 혈압의 현저한 저하틀 유발시키기에 충분한 양과 시간동안 투여함을 특징으로 하는 방법.
- 제14항에 있어서, 인체에 투여되는 비-할로겐화 칼륨염이 중탄산 칼륨임을 특징으로 하는 방법.
- 제14항에 있어서, 인체에 투여되는 비-할로겐화 칼륨염이 인산 칼륨임을 특징으로 하는 방법.
- 비-할로겐화 칼륨염을 포함하며, 고혈압 환자나 정압성 환자내 고혈압중을 치료하기 위해 상기 염을 사용하는 지시가 프린트된 용기.
- 제17항에 있어서, 상기 지시가 용기상에 프린트되어 있음을 특징으로 하는 방법.
- 제17항에 있어서, 상기 염이 중탄산 칼륨임을 특징으로 하는 용기.
- 제17항에 있어서, 상기 염이 인산 칼륨임을 륵징으로 하는 용기.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26085688A | 1988-10-21 | 1988-10-21 | |
US260,856 | 1988-10-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR900701288A true KR900701288A (ko) | 1990-12-01 |
KR0178033B1 KR0178033B1 (ko) | 1999-03-20 |
Family
ID=22990921
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900701332A KR0178033B1 (ko) | 1988-10-21 | 1989-10-20 | 고혈압 치료용 조성물 |
KR1019900701331A KR0163583B1 (ko) | 1988-10-21 | 1989-10-20 | 골다공증 치료용 약제 조성물 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019900701331A KR0163583B1 (ko) | 1988-10-21 | 1989-10-20 | 골다공증 치료용 약제 조성물 |
Country Status (13)
Country | Link |
---|---|
US (1) | US5804204A (ko) |
EP (3) | EP0720855A3 (ko) |
JP (2) | JP2948247B2 (ko) |
KR (2) | KR0178033B1 (ko) |
AT (1) | ATE145825T1 (ko) |
AU (2) | AU635231B2 (ko) |
CA (2) | CA2001123C (ko) |
DE (2) | DE68927519T2 (ko) |
DK (2) | DK175840B1 (ko) |
HU (2) | HU212106B (ko) |
IL (2) | IL92076A (ko) |
WO (2) | WO1990004402A1 (ko) |
ZA (2) | ZA898017B (ko) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5674529A (en) * | 1995-06-06 | 1997-10-07 | Church & Dwight Co., Inc. | Alkalinizing potassium salt controlled release preparations |
AT408416B (de) * | 1996-07-19 | 2001-11-26 | Norbert Fuchs | Pharmazeutische bzw. diätetische zusammensetzungen |
EP1350515A1 (en) * | 2002-04-05 | 2003-10-08 | Btg International Limited | Low-dose potassium supplementation for the prevention and treatment of hypertension |
WO2003086423A1 (en) * | 2002-04-05 | 2003-10-23 | Btg International Limited | Low-dose potassium supplementation for the prevention and treatment of hypertension |
US20040202726A1 (en) * | 2003-04-10 | 2004-10-14 | Deshay Samuel L. | Topical blood pressure composition |
US10251909B2 (en) * | 2007-02-09 | 2019-04-09 | Board Of Regents, The University Of Texas System | Potassium-magnesium citrate as a surrogate of the DASH diet in managing hypertension |
US20090022853A1 (en) * | 2007-07-16 | 2009-01-22 | Conopco, Inc., D/B/A Unilever | Beverage |
MX352695B (es) * | 2008-02-06 | 2017-12-05 | Campbell Soup Co | Metodos y composiciones para reducir el contenido de sodio en productos alimenticios. |
WO2010026136A1 (en) * | 2008-09-05 | 2010-03-11 | Unilever Nv | Beverages comprising potassium |
CN114272263A (zh) * | 2022-01-10 | 2022-04-05 | 伍永田 | 一种用于治疗高血压疾病的水配方 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2611730A (en) * | 1950-09-02 | 1952-09-23 | Simth Kline & French Lab | Medical preparation for reducing the body level of sodium |
GB1195381A (en) * | 1967-04-28 | 1970-06-17 | Arthur H Cox & Company Ltd | Pharmaceutical Compositions Comprising Potassium and Chlorine |
US3639585A (en) * | 1968-03-29 | 1972-02-01 | Res Inst Medicine Chem | Method of preventing corticosteroid-induced adverse effects on bon and compositions useful in said method |
US3541208A (en) * | 1968-09-10 | 1970-11-17 | Arcom Holding Corp | Relief of arthritis with a soluble silicate and a soluble polyphosphate |
US3921804A (en) * | 1974-05-09 | 1975-11-25 | William W Tester | Medication dispensing package |
SU858830A1 (ru) * | 1974-10-23 | 1981-08-30 | Институт медико-биологических проблем | Средство дл лечени нарушений ритма сердца |
SU946545A1 (ru) * | 1978-05-04 | 1982-07-30 | Институт Медико-Биологических Проблем Министерства Здравоохранения Ссср | Способ восполнени калиевого дефицита в ткан х |
FR2432869A1 (fr) * | 1978-08-08 | 1980-03-07 | Armour Montagu Laboratoire | Compositions pour le traitement de l'osteoporose associant la calcitonine et le phosphore |
US4405596A (en) * | 1978-10-16 | 1983-09-20 | Helbig Joachim W | Pharmaceutical preparations for and treatment procedures involving increasing plasma bicarbonate level |
US4289750A (en) * | 1978-10-16 | 1981-09-15 | Kopp Klaus F | Therapy of conditions which may be associated with altered renal function and dosage forms therefor |
US4451454A (en) * | 1981-06-16 | 1984-05-29 | Wong Dennis W | Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals |
US4704269A (en) * | 1985-06-11 | 1987-11-03 | Hudson Pharmaceutical Corporation | Effervescent antacid and analgesic compositions |
JPH0619063B2 (ja) * | 1986-04-09 | 1994-03-16 | 日本エステル株式会社 | 粉体塗料用樹脂組成物 |
-
1989
- 1989-10-20 WO PCT/US1989/004727 patent/WO1990004402A1/en active IP Right Grant
- 1989-10-20 EP EP95119226A patent/EP0720855A3/en not_active Withdrawn
- 1989-10-20 AU AU46220/89A patent/AU635231B2/en not_active Ceased
- 1989-10-20 EP EP89912571A patent/EP0440738B1/en not_active Expired - Lifetime
- 1989-10-20 KR KR1019900701332A patent/KR0178033B1/ko not_active IP Right Cessation
- 1989-10-20 WO PCT/US1989/004771 patent/WO1990004403A1/en active IP Right Grant
- 1989-10-20 CA CA002001123A patent/CA2001123C/en not_active Expired - Fee Related
- 1989-10-20 JP JP1511794A patent/JP2948247B2/ja not_active Expired - Fee Related
- 1989-10-20 HU HU896567A patent/HU212106B/hu not_active IP Right Cessation
- 1989-10-20 KR KR1019900701331A patent/KR0163583B1/ko not_active IP Right Cessation
- 1989-10-20 DE DE68927519T patent/DE68927519T2/de not_active Expired - Fee Related
- 1989-10-20 HU HU896889A patent/HU208923B/hu not_active IP Right Cessation
- 1989-10-20 DE DE68913311T patent/DE68913311T2/de not_active Expired - Fee Related
- 1989-10-20 JP JP2500624A patent/JP2843146B2/ja not_active Expired - Fee Related
- 1989-10-20 CA CA002001124A patent/CA2001124C/en not_active Expired - Fee Related
- 1989-10-20 EP EP89912758A patent/EP0461111B1/en not_active Expired - Lifetime
- 1989-10-20 AT AT89912571T patent/ATE145825T1/de not_active IP Right Cessation
- 1989-10-20 AU AU45154/89A patent/AU634988B2/en not_active Ceased
- 1989-10-22 IL IL9207689A patent/IL92076A/en not_active IP Right Cessation
- 1989-10-22 IL IL9207589A patent/IL92075A/en not_active IP Right Cessation
- 1989-10-23 ZA ZA898017A patent/ZA898017B/xx unknown
- 1989-10-23 ZA ZA898018A patent/ZA898018B/xx unknown
-
1991
- 1991-04-19 DK DK199100727A patent/DK175840B1/da not_active IP Right Cessation
- 1991-04-19 DK DK199100726A patent/DK175841B1/da not_active IP Right Cessation
-
1995
- 1995-06-06 US US08/465,043 patent/US5804204A/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MORROW et al. | Studies on the control of hypertension by Hyphex: II. Toxic reactions and side effects | |
US4424232A (en) | Treatment of herpes simplex | |
HUT60630A (en) | Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature | |
KR900701288A (ko) | 고혈압의 치료 | |
Jager et al. | Dermatomyositis | |
Cotton et al. | Symmetric peripheral gangrene complicating acute myocardial infarction | |
BEAN et al. | Asymmetric cutaneous lesions in pellagra | |
Gillies et al. | Adjunctive effect of salt restriction on antihypertensive efficacy | |
Mitchell | Use of citrated calcium carbimide in alcoholism | |
HENCH et al. | THE PROBLEM OF RHEUMATISM AND ARTHRITIS: Part I | |
Behrendt et al. | General Operative Procedures After Cardiac Valve Replacement: Results and Methods of Management of 33 Patients | |
SU940377A1 (ru) | Способ комплексного лечени звенной болезни желудка и двенадцатиперстной кишки | |
IL82317A0 (en) | 1,4 dihydropyridine derivatives,processes for their preparation and medicaments containing these compounds | |
ROWNTREE | Increasing survival time in Addison's disease: results in six cases in which a noncommercial product of the adrenal cortex and a high salt intake were administered | |
RU2170087C2 (ru) | Способ лечения геморрагического инсульта | |
Frank | COLD FOOT—POSTOPERATIVE SIGN OF SILENT MYOCARDIAL INFARCTION | |
Parker et al. | Possible adverse effect of phenoxybenzamine therapy in a patient with progressive systemic sclerosis | |
BIOLOGICALS | PERSONAL SERVICE | |
Gilder | Overseas Report | |
Dowling | Two cases of Lichen planus | |
Coigley | Essential hypertension and its treatment by the family physician. A study of sixty-one cases. | |
Pemberton et al. | develop all its possibilities. Apart from the practical conclusions drawn, possibly one of the most important results achieved lay in contributing to an hypothesis on | |
Sleep | circulation either remained fairly constant or was moderately | |
MORROW et al. | Studies on the Control of Hypertension | |
Weber | Generalized Sclerodermia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20061114 Year of fee payment: 9 |
|
LAPS | Lapse due to unpaid annual fee |